Structural and mechanistic studies of polymerase η bypass of phenanthriplatin DNA damage
Platinum drugs are a mainstay of anticancer chemotherapy. Nevertheless, tumors often display inherent or acquired resistance to platinum-based treatments, prompting the search for new compounds that do not exhibit cross-resistance with current therapies. Phenanthriplatin, cis-diamminephenanthridinec...
Main Authors: | Gregory, Mark T., Park, Ga Young, Johnstone, Timothy, Lee, Young-Sam, Yang, Wei, Lippard, Stephen J. |
---|---|
Other Authors: | Massachusetts Institute of Technology. Department of Chemistry |
Format: | Article |
Language: | en_US |
Published: |
National Academy of Sciences (U.S.)
2015
|
Online Access: | http://hdl.handle.net/1721.1/92784 https://orcid.org/0000-0002-2693-4982 |
Similar Items
-
Understanding and Improving Platinum Anticancer Drugs - Phenanthriplatin
by: Johnstone, Timothy, et al.
Published: (2015) -
Effect of a Monofunctional Phenanthriplatin-DNA Adduct on RNA Polymerase II Transcriptional Fidelity and Translesion Synthesis
by: Kellinger, Matthew W., et al.
Published: (2014) -
Nucleotide Binding Preference of the Monofunctional Platinum Anticancer-Agent Phenanthriplatin
by: Riddell, Imogen Anne, et al.
Published: (2016) -
The Chiral Potential of Phenanthriplatin and Its Influence on Guanine Binding
by: Lippard, Stephen J., et al.
Published: (2015) -
Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile
by: Park, Ga Young, et al.
Published: (2013)